Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The tumor necrosis factor (TNF) antagonist infliximab was previously found to reduce depressive symptoms in patients with treatment-resistant major depression (TRD) who exhibited high baseline inflammation, as reflected by plasma C-reactive protein (CRP) >5mg/L. Further predictors of antidepressant response to infliximab included differential expression of peripheral blood gene transcripts that were related not only to inflammation but also to glucose and lipid metabolism. To determine whether plasma biomarkers of glucose and lipid metabolism were similarly associated with antidepressant response to infliximab and with relevant gene transcripts, we measured concentrations of glucose, insulin, and protein hormones that regulate glucose homeostasis and metabolism (leptin, resistin, and adiponectin), as well as cholesterols, triglycerides, and non-esterified fatty acids (NEFA), in medically-stable TRD outpatients at baseline and 2 weeks after the first infusion of infliximab (n=26) or placebo (n=26). Treatment response was defined as 50% reduction in depressive symptoms at any point during the 12-week trial. We found that baseline cholesterol (total, low-density lipoprotein [LDL], and non-high-density lipoprotein [non-HDL]), triglycerides and NEFA were elevated in patients who exhibited an antidepressant response to infliximab (all p<0.05) but not placebo (all p>0.299). HDL and non-HDL cholesterol concentrations also correlated with two lipid-related gene transcripts that were predictive of antidepressant response (r=0.33 to 0.39, p<0.05). Although not associated with response to infliximab, resistin correlated with numerous glucose-related transcripts (r=−0.32 to 0.37, p<0.05) and was higher at 2 weeks post-infusion in patients treated with infliximab compared to placebo (p=0.028). Concentrations of cholesterol (total, LDL, HDL, non-HDL) were also lower at 2 weeks in patients treated with infliximab compared to placebo, but only in those patients with CRP >5mg/L at baseline (all p<0.05). These results are consistent with previous work showing that high inflammation in patients with depression is associated with metabolic alterations, which together predict response to both traditional and experimental antidepressant therapies. Additionally, our findings suggest a causal relationship between increased inflammation and high cholesterol in depression, as a single infusion of infliximab reduced cholesterol in TRD patients with high CRP compared to placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Depression is a heterogenous and widespread disorder with a lifetime prevalence >20% (Hasin et al., 2018) that confers increased risk for medical illnesses which are known to be associated with inflammation, obesity and/or metabolic dysregulation including cardiovascular disease, diabetes, and cancer (Currier and Neme…”
BackgroundRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 8×
“…of infliximab versus placebo in TRD patients, defined as patients with MDD or bipolar disorder who were depressed and non-responsive to antidepressant treatment as determined by a score ≥2 on the Massachusetts General Hospital Staging (MGH-S) method in the current episode (Raison et al., 2013).”
BackgroundMethodResultInfluentialSelf-citationThe Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.580 · Cited by 1,532
Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6
Park, H. S., Park, J. Y., & Yu, R. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.11.007 · Cited by 964
WikiPathways: Pathway Editing for the People
Pico, A. R., Kelder, T., van Iersel, M. P., Hanspers, K., Conklin, B. R., & Evelo, C. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060184 · Cited by 701 · cited 1×
“Joseph, MI) or the Wikipathways tool via the Webgestalt interface (Pico et al., 2008) found 5 genes associated with glycolysis and gluconeogenesis and 3 genes associated with lipid metabolism (cholesterol and sphingolipid transport) to be the most predictive gene transcripts (Mehta et al.”
MethodSurrogate markers of insulin resistance: A review
Singh, B. (2010) · World Journal of Diabetes · doi:10.4239/wjd.v1.i2.36 · Cited by 622 · cited 2×
“Plasma adiponectin has previously been found to negatively correlate with BMI and insulin resistance (Singh and Saxena, 2010; Tschritter et al., 2003), providing biological support for this finding.”
MethodResultFelger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung, M. Y., Hu, X., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.168 · Cited by 620
Self-citationInflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584 · cited 1×
“Inflammatory cytokines that are produced in the periphery are known to access the central nervous system and to affect neurotransmitters and neural circuits that contribute to the behavioral symptoms of depression (Capuron et al., 2017; Felger, 2018; Felger and Treadway, 2017; Haroon et al., 2017).”
BackgroundSelf-citationWhat does plasma CRP tell us about peripheral and central inflammation in depression?
Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A., Feinberg, R., Tansey, M. G., & Miller, A. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0096-3 · Cited by 448 · cited 3×
“3 qualified for loading a component (Felger et al., 2018; Grimsholm et al., 2005).”
BackgroundMethodSelf-citationCattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Raison, C. L., Borisov, A. S., Majer, M., Drake, D. F., Pagnoni, G., Woolwine, B. J., Vogt, G. J., Massung, B., & Miller, A. H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.010 · Cited by 367 · cited 1×
“Non-normal markers were natural log (ln) transformed for parametric statistics, consistent with previous analyses (Haroon et al., 2014; Haroon et al., 2016; Raison et al., 2009; Torres et al., 2013).”
ResultSelf-citationHigh-Fat Diet Induced Anxiety and Anhedonia: Impact on Brain Homeostasis and Inflammation
Dutheil, S., Ota, K. T., Wohleb, E. S., Rasmussen, K., & Duman, R. S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.357 · Cited by 355
Haroon, E., Fleischer, C. C., Felger, J. C., Chen, X., Woolwine, B. J., Patel, T., Hu, X. P., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.206 · Cited by 250
Self-citationTam, L.-S., Tomlinson, B., Chu, T. T., Li, T. K., & Li, E. K. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0539-8 · Cited by 197
Role of Adiposity-Driven Inflammation in Depressive Morbidity
Capuron, L., Lasselin, J., & Castanon, N. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.123 · Cited by 182 · cited 15×
“No differences in gender, age, ethnicity, BMI, CRP, baseline HAM-D-17 depression scores, or the number of individuals on current antidepressants, mood stabilizers, antipsychotic medicines, and psychotropic medicines were observed between the responders and non-responders in either treatment group (all p>0.05).”
BackgroundInfluentialTherapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152 · cited 13×
“No differences in gender, age, ethnicity, BMI, CRP, baseline HAM-D-17 depression scores, or the number of individuals on current antidepressants, mood stabilizers, antipsychotic medicines, and psychotropic medicines were observed between the responders and non-responders in either treatment group (all p>0.05).”
BackgroundInfluentialSelf-citationRethorst, C. D., Bernstein, I., & Trivedi, M. H. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09009 · Cited by 152 · cited 1×
“In this regard, 30–50% of patients with depression are reported to have high levels of inflammatory markers, including the acute phase reactant Creactive protein (CRP), as well as high body mass index (BMI), and/or markers of metabolic dysregulation, all of which may predispose patients to the development of co-morbid…”
BackgroundDepression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications
Currier, M. B., & Nemeroff, C. B. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061212-171507 · Cited by 126 · cited 1×
“, 2018) that confers increased risk for medical illnesses which are known to be associated with inflammation, obesity and/or metabolic dysregulation including cardiovascular disease, diabetes, and cancer (Currier and Nemeroff, 2014; Musselman et al., 2003; Musselman et al., 1998).”
BackgroundMehta, D., Raison, C. L., Woolwine, B. J., Haroon, E., Binder, E. B., Miller, A. H., & Felger, J. C. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.004 · Cited by 74 · cited 8×
“Furthermore, a single dose of infliximab modified expression levels of both inflammatory and metabolic-related gene transcripts 2 weeks post-infusion in responders, suggesting that reducing inflammation may have also improved metabolic function in these patients (Mehta et al., 2013).”
BackgroundMethodInfluentialSelf-citationKiecolt-Glaser, J. K., Fagundes, C. P., Andridge, R., Peng, J., Malarkey, W. B., Habash, D., & Belury, M. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.149 · Cited by 54
Cited by
C-Reactive protein as a biomarker for major depressive disorder?
Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., & Volpe, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031616 · Cited by 171
“, nonsteroidal anti-inflammatory drugs or anti-cytokine) could be useful in the treatment of depression [128–131], despite findings so far are contradictory [96,132,133].”
BackgroundMetabolomic and inflammatory signatures of symptom dimensions in major depression
Brydges, C. R., Bhattacharyya, S., Dehkordi, S. M., Milaneschi, Y., Penninx, B., Jansen, R., Kristal, B. S., Han, X., Arnold, M., Kastenmüller, G., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.02.003 · Cited by 108
Self-citationClinical phenotypes of depressed patients with evidence of inflammation and somatic symptoms
Foley, É. M., Parkinson, J. T., Kappelmann, N., & Khandaker, G. M. (2021) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2021.100079 · Cited by 34
Neuroimmune Advance in Depressive Disorder
Zhao, G., & Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9271-0_4 · Cited by 20
Wang, F., Guo, L., Zhang, T., Cui, Z., Wang, J., Zhang, C., Xue, F., Zhou, C., Li, B., Tan, Q., et al. (2022) · Medicina · doi:10.3390/medicina58111509 · Cited by 18
Metadata
- Authors
- Bekhbat, M., Chu, K., Le, N.-A., Woolwine, B. J., Haroon, E., Miller, A. H., & Felger, J. C.
- Venue
- Psychoneuroendocrinology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 98
- Pages
- 222-229
- ISSN
- 0306-4530 (ISSN-L)
- OpenAlex
- W2889773014
- Cited by
- 64
- References
- 20
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.